Faı̈ez Zannad
A5036821495- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Diabetes Treatment and Management
- Hormonal Regulation and Hypertension
- Blood Pressure and Hypertension Studies
- Cardiac pacing and defibrillation studies
- Potassium and Related Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Electrolyte and hormonal disorders
- Pancreatic function and diabetes
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
- Cardiac Fibrosis and Remodeling
- Heart Rate Variability and Autonomic Control
- Cardiovascular and exercise physiology
- Lipoproteins and Cardiovascular Health
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Health and Disease Prevention
- GDF15 and Related Biomarkers
- Diabetes Management and Research
- Chronic Kidney Disease and Diabetes
- Hemodynamic Monitoring and Therapy
- Dialysis and Renal Disease Management
- Mechanical Circulatory Support Devices
- Cardiac Arrhythmias and Treatments
Inserm
2016-2025
Centre d'Investigation Clinique Pierre Drouin
2016-2025
Défaillance Cardiovasculaire Aiguë et Chronique
2016-2025
French Clinical Research Infrastructure Network
2016-2025
Université de Lorraine
2016-2025
Centre Hospitalier Régional et Universitaire de Nancy
2015-2024
Universidade do Porto
2017-2024
National Heart Centre Singapore
2024
British Heart Foundation
2012-2024
National Heart Hospital
2024
The ESH/ESC Guidelines represent the views of ESH and ESC were arrived at after careful consideration available evidence time they written.Health professionals are encouraged to take them fully into account when exercising their clinical judgement.The guidelines do not, however, override individual responsibility health make appropriate decisions in circumstances patients, consultation with that patient, where necessary patient's guardian or carer.It is also professional's verify rules...
Aldosterone is important in the pathophysiology of heart failure. In a doubleblind study, we enrolled 1663 patients who had severe failure and left ventricular ejection fraction no more than 35 percent were being treated with an angiotensin-converting-enzyme inhibitor, loop diuretic, most cases digoxin. A total 822 randomly assigned to receive 25 mg spironolactone daily, 841 placebo. The primary end point was death from all causes.The trial discontinued early, after mean follow-up period 24...
ESC guidelines for the diagnosis and treatment of acute chronic heart failure 2012 : The Task Force Diagnosis Treatment Acute Chronic Heart Failure European Society Cardiology. Developed in collaboration with Association (HFA)
Table of Contents Introduction Principles New aspects Epidemiological Relationship blood pressure to cardiovascular and renal damage Definition classification hypertension Prevalence Hypertension total risk Assessment Limitations Summary recommendations on assessment Diagnostic evaluation Bood measurement Office or clinic Out-of-office White-coat (or isolated office) masked ambulatory) Clinical indications for out-of-office Blood during exercise laboratory stress Central Medical history...
Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, selective aldosterone blocker, on acute myocardial infarction complicated by left ventricular dysfunction
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless presence or absence diabetes. More evidence is needed regarding effects these drugs across broad spectrum failure, including those with a markedly reduced ejection fraction.
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with and a reduced ejection fraction, but their effects preserved fraction are uncertain.
PITT, BERTRAM; ZANNAD, FAIEZ; REMME, WILLEM J.; CODY, ROBERT; CASTAIGNE, ALAIN; PEREZ, ALFONSO; PALENSKY, JOLIE; WITTES, JANET FOR THE RANDOMIZED ALDACTONE EVALUATION STUDY INVESTIGATORS Author Information
Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and after myocardial infarction. We evaluated the effects of eplerenone in chronic mild symptoms.
To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the safety profile antidiabetic therapies. We assessed outcomes alogliptin, inhibitor dipeptidyl peptidase 4 (DPP-4), as compared placebo diabetes who had recent acute coronary syndrome.We randomly assigned and either an myocardial infarction or unstable angina requiring hospitalization within previous 15 90 days...
<h3>Context</h3>Guidelines recommend that exercise training be considered for medically stable outpatients with heart failure. Previous studies have not had adequate statistical power to measure the effects of on clinical outcomes.<h3>Objective</h3>To test efficacy and safety among patients failure.<h3>Design, Setting, Patients</h3>Multicenter, randomized controlled trial 2331 failure reduced ejection fraction. Participants in Heart Failure: A Controlled Trial Investigating Outcomes Exercise...
Statins reduce the incidence of cardiovascular events in patients at high risk. However, a benefit statins such who are undergoing hemodialysis has not been proved.We conducted an international, multicenter, randomized, double-blind, prospective trial involving 2776 patients, 50 to 80 years age, were maintenance hemodialysis. We randomly assigned receive rosuvastatin, 10 mg daily, or placebo. The combined primary end point was death from causes, nonfatal myocardial infarction, stroke....
The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with and ejection fraction. effect inhibition in preserved fraction is unclear.
ContextVasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of failure.ObjectiveTo investigate the effects tolvaptan initiated patients hospitalized with failure.Design, Setting, and ParticipantsThe Efficacy Vasopressin Antagonism Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double-blind, placebo-controlled study. The outcome trial comprised 4133 within 2 short-term clinical...
Intima-media thickness (IMT) is increasingly used as a surrogate end point of vascular outcomes in clinical trials aimed at determining the success interventions that lower risk factors for atherosclerosis and associated diseases (stroke, myocardial infarction peripheral artery diseases). The necessity to promote further criteria distinguish early atherosclerotic plaque formation from thickening IMT standardize measurements expressed through this updated consensus. Plaque defined focal...
Nesiritide is approved in the United States for early relief of dyspnea patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and mortality associated this agent.We randomly assigned 7141 who were hospitalized failure to receive either nesiritide or placebo 24 168 hours addition standard care. Coprimary end points change at 6 hours, as measured on a 7-point Likert scale, composite point rehospitalization death within 30 days.Patients...
1. INTRODUCTION 1.1 Principles The 2013 European Society of Hypertension/European Cardiology (ESH/ESC) guidelines continue to adhere some fundamental principles that inspired the 2003 and 2007 guidelines, namely base recommendations on properly conducted studies identified from an extensive review literature; consider, as highest priority, data randomized, controlled trials their meta-analyses, but not disregard results observational other appropriate scientific calibre; grade level evidence...
Background— Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept heart failure. Methods Results— Patients with New York Heart Association class II to IV chronic failure left ventricular ejection fraction ≤0.30 were enrolled 2 trials that differed only doses of used. In RECOVER, patients received placebo (n=373) or subcutaneous 25 mg every week (n=375) twice per (n=375)....
Central sleep apnea is associated with poor prognosis and death in patients heart failure. Adaptive servo-ventilation a therapy that uses noninvasive ventilator to treat central by delivering servo-controlled inspiratory pressure support on top of expiratory positive airway pressure. We investigated the effects adaptive who had failure reduced ejection fraction predominantly apnea.We randomly assigned 1325 left ventricular 45% or less, an apnea-hypopnea index (AHI) 15 more events...
Background —In congestive heart failure (CHF), extracellular matrix turnover is a major determinant of cardiac remodeling. It has been suggested that spironolactone may decrease fibrosis. We investigated the interactions between serum markers fibrosis and effect on outcome in patients with CHF. Methods Results —A sample 261 from Randomized Aldactone Evaluation Study (RALES) were randomized to placebo or (12.5 50 mg daily). Serum procollagen type I carboxy-terminal peptide, amino-terminal III...